Cargando…

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis

This study aimed to directly analyze the potential relationship of anti-nuclear antibodies (ANA) before and after the administration of TNF-α inhibitors (TNFi) with the appearance of anti-drug antibodies (ADrA) in patients with rheumatoid arthritis (RA). A total of 121 cases, viz., 38, 53, and 30 ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Ayano, Saito, Toshiharu, Takahashi, Miho, Shibata, Miho, Tsuji, Goh, Hatachi, Saori, Takahashi, Soshi, Kumagai, Shunichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735569/ https://www.ncbi.nlm.nih.gov/pubmed/33315881 http://dx.doi.org/10.1371/journal.pone.0243729

Ejemplares similares

Usefulness of position emission tomography/computed tomography in a case of sarcoidosis with multiorgan involvement
por: Amano, Norihiko, et al.
Publicado: (2022)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
por: Afonso, Joana, et al.
Publicado: (2016)

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
por: Gils, Ann, et al.
Publicado: (2014)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
por: van Damme, N, et al.
Publicado: (2002)

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab
por: Cludts, Isabelle, et al.
Publicado: (2017)

Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review
por: Valdes, Lianna, et al.
Publicado: (2022)

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
por: Berger, Anne Emmanuelle, et al.
Publicado: (2022)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
por: Toja-Camba, Francisco José, et al.
Publicado: (2023)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
por: Rocha, Cátia, et al.
Publicado: (2020)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Concomitant appearance of anti-cardiolipin, anti-β(2)-glycoprotein I, anti-prothrombin and anti-annexin V antibodies
por: Cucnik, S, et al.
Publicado: (2004)

Development of Disseminated Tuberculosis with Intestinal Involvement due to Adalimumab Administration Despite Latent Tuberculosis Treatment
por: Ikuta, Kozo, et al.
Publicado: (2019)

Detection of anti-ebolavirus antibodies in Ghanaian pigs
por: OGAWA, Hirohito, et al.
Publicado: (2022)

Presence of Circulating Anti-Myosin Antibodies in Endomyocardial Fibrosis
por: Mocumbi, Ana Olga, et al.
Publicado: (2010)

Induction of ANA, anti-dsDNA and anti-nucleosome antibodies following infliximab treatment in rheumatoid arthritis and spondyloarthropathy patients
por: de Rycke, LEB, et al.
Publicado: (2002)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Presence of Anti-Thyroid Antibodies Correlate to Worse Outcome of Anti-NMDAR Encephalitis
por: Chen, Zhongyun, et al.
Publicado: (2021)

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
por: Eng, Grith Petersen, et al.
Publicado: (2016)

Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçet's disease with uveitis
por: Ishigatsubo, Y, et al.
Publicado: (2015)

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels
por: Xiang, Dong, et al.
Publicado: (2023)

Effects of Adalimumab, an Anti-tumour Necrosis Factor-Alpha (TNF-α) Antibody, on Obese Diabetic Rats
por: Shuwa, Halima Ali, et al.
Publicado: (2018)

Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment
por: Chandra, Tanya, et al.
Publicado: (2019)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Presence of anti-nuclear antibody associated with worse clinical outcomes of anti-NMDAR encephalitis
por: Lei, Chunyan, et al.
Publicado: (2022)

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
por: Lee, Jung Hoon, et al.
Publicado: (2007)

Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions
por: Vultaggio, A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gqckcdhn4r9v6egerqqc90m8is